DEFEROXAMINE MESYLATE FOR INJECTION 2 G
DEFEROXAMINE MESYLATE : 2 G · DIN 02247022 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is DEFEROXAMINE MESYLATE FOR INJECTION?
DEFEROXAMINE MESYLATE FOR INJECTION 2 G contains DEFEROXAMINE MESYLATE : 2 G. It is listed in the Health Canada Drug Product Database under DIN 02247022, held by PFIZER CANADA ULC, supplied as POWDER FOR SOLUTION for INTRAPERITONEAL ; INTRAMUSCULAR ; SUBCUTANEOUS ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 08-Aug-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DEFEROXAMINE MESYLATE FOR INJECTION used for?
Deferoxamine Mesylate for Injection is indicated for: • Acute iron intoxication. • Chronic iron overload due to transfusion-dependent anemias. • Diagnosis of aluminum overload (deferoxamine infusion test). • Chronic aluminum overload in patients with End-Stage Renal Failure (ESRF) under maintenance dialysis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02247022 |
|---|---|
| Brand name | DEFEROXAMINE MESYLATE FOR INJECTION |
| Generic / active ingredient | DEFEROXAMINE MESYLATE : 2 G |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 2 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAPERITONEAL ; INTRAMUSCULAR ; SUBCUTANEOUS ; INTRAVENOUS |
| Schedule | Prescription |
| ATC code | V03AC01 DEFEROXAMINE |
| AHFS class | 64:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 08-Aug-2018 |
| Original market date | 2004-01-12 00:00:00 |
How is it administered?
Administer parenterally (IV, IM, or SC). Max 6.0 g/24h. IV rate should not exceed 15 mg/kg/h. Dosage depends on severity of intoxication or overload.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
500 mg deferoxamine mesylate /vial, 2 g deferoxamine mesylate /vial
Contraindications
Hypersensitivity to deferoxamine mesylate or any component of the container, except where desensitization is successful.
Warnings and precautions
Rapid IV injection (>15 mg/kg/h) can cause shock. Risk of hearing/visual disturbances. Risk of Yersinia infections and mucormycosis. Acute respiratory distress syndrome at excessive doses.
What can be used instead?
Other Canadian products sharing ATC code V03AC01 DEFEROXAMINE. 3 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DEFEROXAMINE MESYLATE FOR INJECTION | 500 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02241600 |
| DESFERAL 500MG | 500 MG | POWDER FOR SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 01981242 |
| DEFEROXAMINE MESYLATE FOR INJECTION | 2 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02261820 |
| DESFERAL 2G | 2 G | POWDER FOR SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 01981250 |
| PMS-DEFEROXAMINE | 2 G | POWDER FOR SOLUTION | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02243450 |
| PMS-DEFEROXAMINE | 500 MG | POWDER FOR SOLUTION | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02242055 |
Who else supplies DEFEROXAMINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DEFEROXAMINE appears in 22 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.